Replies to post #9597 on Biotech Values

[poorgradstudent]

I didn't go to the website to look for additional info.

I went to pubmed.

Again, I see nothing in Genara's presentation of its MOA that is more or less explicit than other companies trying to retrofit an MOA to a previously existing compound. For example, it is initially hard to see why calmodulin is the prime target for their focus rather than the 2 or 3 more abundant signals in their affinity chromatography... until you look at pubmed and see that calmodulin provides an easy way for them to link their drug to a large collection of cell processes.

>they have provided a clear enough conceptual look into Evizon's MOA <

What they did was provide a conceptual look that has the buzzwords that they feel will attract investors. VEGF, angiogenesis, apoptosis etc.. It's not an indictment of Genaera specifically, just a reflection of the research capacities and requirements of smaller companies versus larger companies.